Long-term outcome. (A) LFS of all patients who received sequential CAR T-cell therapy. (B) Overall survival of patients who received sequential CAR T-cell therapy. (C) LFS comparison after CAR T-cell therapy between patients without or with the TP53 mutation. (D) Normal CD19⁺ B cells in every patient’s BM after sequential CD19 and CD22 therapy. The red lines indicate patients with relapse, and the last time point represents the diagnosis of relapse. (E) Recovery of immunoglobulin and normal B cells in BM among 20 patients, determined by immunoturbidimetry and FCM, respectively. (F) The probability of relapse rate associated with immunoglobulin recovery. (G) Leukemic CD19 and CD22 expression in the 3 patients with relapse, determined by FCM. In panels A and B, dashed lines indicate 95% confidence intervals. In all panels, the tick marks indicate the time of data censored at the last follow-up.